stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Shares outstanding
Replimune Group, Inc.'s shares outstanding at the end of fiscal 2026 was $92.8M, up 15.2% from $80.6M in fiscal 2025. At the end of the quarter to 30 September 2026 it was $105.2M. Over the past ten years it has ranged from $5.0M (fiscal 2017) to $92.8M (fiscal 2026) — the current reading is the highest in ten years. Replimune Group, Inc. ranks 140th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $92.8M | 15.19% |
| FY2025 | $80.6M | 21.02% |
| FY2024 | $66.6M | 14.36% |
| FY2023 | $58.2M | 11.49% |
| FY2022 | $52.2M | 12.89% |
| FY2021 | $46.2M | 34.99% |
| FY2020 | $34.3M | 47.69% |
| FY2019 | $23.2M | 365.92% |
| FY2018 | $5.0M | 0.12% |
| FY2017 | $5.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $105.2M | 8.58% |
| Jun 2026 | $96.9M | 4.37% |
| Mar 2026 | $92.8M | 0.67% |
| Dec 2025 | $92.2M | 0.30% |
| 34 more quarters | Free account |
Against its own ten years
Low $5.0M
High $92.8M
Ten-year median
$49.2M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| VIR Vir Biotechnology, Inc. compare | $169.3M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.6M |
| REPL Replimune Group, Inc. | $105.2M |
| ZYME Zymeworks Inc. compare | $76.3M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $35.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item